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Being less than 5% of all plasma cell disorders, most publications on plasma cell 
leukaemia (PCL) are based on case reports. In 2005 a 57- year- old man was admitted to 
our institution because of edema and dyspnea. He had a 1- month history of fatigue, 
anorexia, weight loss of 8 kg and a sharply delimited dorsal pain. Physical examination 
revealed pallor, hepatomegaly and edema. Laboratory data were as follows: hemoglobin 
9.9 g/dl, white blood cell count 10.7× 10 
9
 /l with 65% plasmacytoid lymphocytes, urea 
of 580 mg/l and creatinine of 34 mg/l. Calcium was elevated as well as β2 - 
microglobulin (26144 ng/ml). There was no M- component. A skeletal bone survey 
showed an osteolytic lesion at the dorsal spine with fracture and small lesions at the 
lumbar spine. Ultrasonography revealed no renal alterations. Urine protein 
electrophoresis showed κ light chains 0.0068 g/l and λ light chains 3.91 g/l; 24- h urine 
collection revealed 12 gr of proteins. A bone marrow examination revealed 
hypercellularity with a 70% infiltration of plasma cells and a blood smear with a 24% 
infiltration, which were CD38- positive, CD 138- positive and CD20- negative. The 
DNA content study showed hyperploidy. The renal biopsy revealed a massive 
infiltration of the tubulointerstitial compartment by plasma cells and heavy deposition 
of l- light chains [Figure 1] with no amyloid substance. We administered a VAD 
regimen on days 1- 4, 9- 12 and 17- 20 at 4- week intervals.  
 
Figure 1: Kidney biopsy showing a diffuse infiltrate of 
atypical plasma cells mainly at the tubulointerstitial 
compartment (hematoxylin- eosin stain, original 
magnification × 400 , a) and λ light chains (b) 
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Despite aggressive chemotherapy regimen, response to treatment is still poor and 
successful therapeutic regimen has not been yet established. 
[1],[2]
 Our patient was 
treated following the VAD regimen having received five courses at 4- week intervals 
without hematological remission. The patient died from tumor progression 4 months 
post -diagnosis. 
 
Up till now, immunophenotypic studies have shown that myeloma cells from PCL 
characteristically do not express CD56. 
[3]
 These data lead some authors to consider the 
absence of CD56 as a hallmark of PCL and that could discriminates it from MM. Here 
relies a striking difference of our report were the CD56- positivity is not in agreement 
with the vast majority of the medical literature (most works report CD56 - negativity). 
Very few cases have studied DNA cell content in their reports; the vast majority of 
cases have a DNA index of 1 or less. 
[4]
 Here is another difference since our patient 
displayed hyperdiploidy.  
 
The hematological malignancies associated with nephrotic syndrome are mainly due to 
Hodgkin and non- Hodgkin's lymphoma and chronic lymphocytic leukemia. Renal 
disease occurs in up to 50% of patients with MM and sometimes, more than one is seen. 
Being multifactorial, renal dysfunction attributable to leukemic infiltration is rare and 
mainly described for chronic lymphocytic leukaemia. 
[5]
 To the best of our knowledge 
no case of such massive kidney infiltration by plasma cells has previously been 
reported. Renal failure has the potential to substantially jeopardize the chances of cancer 
patients receiving optimal treatment. The strategy has to consider both plasma cell clone 
and renal manifestations being necessarily a combined approach, which was not 
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  [Figure 1]  
Figure 1: Kidney biopsy showing a diffuse infiltrate of atypical plasma cells mainly at 
the tubulointerstitial compartment (hematoxylin- eosin stain, original magnification × 
400 , a) and λ light chains (b) 
 
   
 
 
